• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Smc Holdings Ii, Lp

    12/8/23 4:16:07 PM ET
    $OSA
    Medical Specialities
    Health Care
    Get the next $OSA alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    SMC Holdings II, LP

    (Last) (First) (Middle)
    C/O SPRING MOUNTAIN CAPITAL, LP
    650 MADISON AVE., 20TH FLOOR

    (Street)
    NEW YORK NY 10022

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    ProSomnus, Inc. [ OSA ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    12/06/2023
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    Form filed by One Reporting Person
    X Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Warrants $1 12/06/2023 J(1)(2) 2,228,484 12/06/2023 09/20/2028 Common Stock 2,228,484 (1)(2) 2,228,484 D(5)
    Series A Convertible Preferred Stock $1 12/06/2023 J(1)(2) 2,338,154 12/06/2023 (6) Common Stock 2,338,154 (1)(2) 2,338,154 D(5)
    Subordinated Secured Convertible Notes Due April 6, 2026 $1 12/06/2023 J(3)(4) 2,630,289 12/06/2023 04/06/2026 Common Stock 2,630,289 (3)(4) 2,630,289 D(5)
    1. Name and Address of Reporting Person*
    SMC Holdings II, LP

    (Last) (First) (Middle)
    C/O SPRING MOUNTAIN CAPITAL, LP
    650 MADISON AVE., 20TH FLOOR

    (Street)
    NEW YORK NY 10022

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    SMC Holdings II G.P., LLC

    (Last) (First) (Middle)
    C/O SPRING MOUNTAIN CAPITAL, LP
    650 MADISON AVENUE, 20TH FLOOR

    (Street)
    NEW YORK NY 10022

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    Steffens John

    (Last) (First) (Middle)
    C/O SPRING MOUNTAIN CAPITAL, LP
    650 MADISON AVENUE, 20TH FLOOR

    (Street)
    NEW YORK NY 10022

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    Ho Gregory P.

    (Last) (First) (Middle)
    C/O SPRING MOUNTAIN CAPITAL, LP
    650 MADISON AVENUE, 20TH FLOOR

    (Street)
    NEW YORK NY 10022

    (City) (State) (Zip)
    Explanation of Responses:
    1. On September 20, 2023, the Issuer entered into a Securities Purchase Agreement (the "SPA") with SMC Holdings II, LP, a Delaware limited partnership ("Holdings"), and the other investors named therein, pursuant to which Holdings purchased an aggregate of (A) 3,300 shares of the Series A Convertible Preferred Stock of the Issuer ("Series A Stock"), with 2,400 shares being purchased at a closing on September 20, 2023 and 900 shares purchased at a closing on October 20, 2023, and (B) warrants ("Warrants") to purchase 2,228,484 shares of the common stock of the Issuer ("Common Stock"). Each share of Series A Stock is convertible into 1,000 shares of Common Stock. Prior to the date on which the Issuer obtained stockholder approval for all of the Common Stock issuable in respect of the convertible securities issued pursuant to or contemplated by the SPA ("Stockholder Approval"),
    2. (Continued from Footnote 1) the Warrants were not exercisable and Holdings could only convert its shares of Series A Stock into an aggregate of 961,846 shares of Common Stock. Following the receipt of Stockholder Approval on December 6, 2023, all of the Warrants became exercisable, and the Series A Stock became convertible into 3,300,000 shares of Common Stock. This Form 4 reports the acquisition of beneficial ownership of all of the shares of Common Stock issuable upon exercise of the Warrants and of the additional 2,338,154 shares of Common Stock issuable upon conversion of the Series A Stock as a result of the receipt of Stockholder Approval. The foregoing description is not, and does not purport to be, complete, and is qualified in its entirety by reference to the full text of the SPA, which was filed as Exhibit 10.1 to the Form 8-K filed by the Issuer with the Securities and Exchange Commission on September 21, 2023.
    3. On October 11, 2023, the Issuer entered into an Exchange Agreement with the noteholders party thereto, including Holdings, pursuant to which the Issuer issued to Holdings a new subordinated secured convertible note due April 6, 2026 in the principal amount of $3,256,549 (the "Convertible Note") in exchange for the subordinated secured convertible note due April 6, 2026 that the Issuer originally issued to Holdings on or about December 6, 2022. Prior to the receipt of Stockholder Approval, the Convertible Note was convertible into shares of Common Stock at a conversion price of $5.20 per share for an aggregate of 626,260 shares of Common Stock. Following the receipt of Stockholder Approval, the Convertible Note became convertible into Common Stock at a conversion price of $1.00 per share for an aggregate of 3,256,549 shares of Common Stock.
    4. (Continued from Footnote 3) This Form 4 reports the acquisition of beneficial ownership of an additional 2,630,289 shares of Common Stock issuable upon conversion of the Convertible Note as a result of the receipt of Stockholder Approval. The Convertible Note is currently exercisable.
    5. The reported securities are directly owned by Holdings, and may be deemed to be indirectly beneficially owned by SMC Holdings II G.P., LLC, a Delaware limited liability company ("Holdings GP"), as general partner of Holdings. The reported securities may also be deemed to be indirectly beneficially owned by each of John L. Steffens and Gregory P. Ho, as the managing members of Holdings GP. Each of Holdings GP, Mr. Steffens and Mr. Ho disclaims beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this filing shall not be deemed an admission that he or it is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
    6. The Series A Stock is perpetual and therefore has no expiration date.
    SMC Holdings II, LP, by SMC Holdings II G.P., LLC, as its general partner, By: /s/ Gregory P. Ho 12/08/2023
    SMC Holdings II G.P., LLC, by Gregory P. Ho, as Managing Member, By: /s/ Gregory P. Ho 12/08/2023
    /s/ John L. Steffens 12/08/2023
    /s/ Gregory P. Ho 12/08/2023
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $OSA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OSA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $OSA
    SEC Filings

    View All

    ProSomnus Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Creation of a Direct Financial Obligation, Events That Accelerate or Increase a Direct Financial Obligation, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - ProSomnus, Inc. (0001934064) (Filer)

    5/8/24 9:25:27 AM ET
    $OSA
    Medical Specialities
    Health Care

    ProSomnus Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    8-K - ProSomnus, Inc. (0001934064) (Filer)

    4/30/24 4:51:50 PM ET
    $OSA
    Medical Specialities
    Health Care

    SEC Form 10-K/A filed by ProSomnus Inc. (Amendment)

    10-K/A - ProSomnus, Inc. (0001934064) (Filer)

    4/29/24 5:29:15 PM ET
    $OSA
    Medical Specialities
    Health Care

    $OSA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Kim Sung was granted 315,742 shares, increasing direct ownership by 157% to 516,808 units (SEC Form 4)

    4 - ProSomnus, Inc. (0001934064) (Issuer)

    2/16/24 6:20:29 PM ET
    $OSA
    Medical Specialities
    Health Care

    Dow Brian B was granted 315,742 shares, increasing direct ownership by 337% to 409,492 units (SEC Form 4)

    4 - ProSomnus, Inc. (0001934064) (Issuer)

    2/16/24 6:16:43 PM ET
    $OSA
    Medical Specialities
    Health Care

    Liptak Len was granted 1,322,756 shares, increasing direct ownership by 208% to 1,957,216 units (SEC Form 4)

    4 - ProSomnus, Inc. (0001934064) (Issuer)

    2/16/24 6:14:33 PM ET
    $OSA
    Medical Specialities
    Health Care

    $OSA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ProSomnus Reports Record Fourth Quarter and Fiscal Year 2023 Financial Results

    PLEASANTON, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ:OSA), the leading non-CPAP therapy™ for the treatment of Obstructive Sleep Apnea (OSA), today announced financial results for the fourth quarter and year ended December 31, 2023. Recent Business Highlights Generated record revenues of $7.8 million for the fourth quarter and $27.7 million for the fiscal year 2023, a 35% increase compared to $5.8 million for the fourth quarter 2022 and 43% increase compared to $19.4 million for fiscal year 2022. The quarter marked the eighth (8th) sequential quarter of record revenues.Continued focus on implementing reductions in operating expenses. Operating expenses, excludin

    3/26/24 4:05:00 PM ET
    $OSA
    Medical Specialities
    Health Care

    ProSomnus Reschedules Fourth Quarter and Fiscal Year 2023 Investor and Business Update Call

    PLEASANTON, Calif., March 15, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the "Company"), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced today it has postponed the release of its 2023 fourth quarter and full year financial results and the related investor conference call. The rescheduled call will be held after market close on Tuesday, March 26, 2024 at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Registration and dial-in information can be found on the investor relations website. Additionally, the Company will not be attending the Roth Conference. About ProSomnusProSomnus (NASDAQ: OSA) is the leading non-CPAP therapy for the treatment of Obstructiv

    3/15/24 8:01:20 PM ET
    $OSA
    Medical Specialities
    Health Care

    ProSomnus Reports Successful Pilot Study Validation of Next Generation Remote Patient Monitoring Device for Obstructive Sleep Apnea

    PLEASANTON, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ:OSA) (the "Company"), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced results of its pilot study for the Company's Next Generation Remote Patient Monitoring (RPM) device for Obstructive Sleep Apnea (OSA). Data from the pilot study demonstrated that an oximeter embedded in a precision medical device can accurately, safely, and continuously monitor SpO2. "This pilot study validation represents a step toward bringing sleep medicine into the P4 medicine era. The ProSomnus® RPMO2 OSA Device enables sleep medicine to be more personalized, predictive, preventative, and participatory," commented L

    2/22/24 8:30:00 AM ET
    $OSA
    Medical Specialities
    Health Care

    $OSA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by ProSomnus Inc.

    SC 13G - ProSomnus, Inc. (0001934064) (Subject)

    2/14/24 11:10:52 AM ET
    $OSA
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by ProSomnus Inc. (Amendment)

    SC 13G/A - ProSomnus, Inc. (0001934064) (Subject)

    2/12/24 11:46:53 AM ET
    $OSA
    Medical Specialities
    Health Care

    SEC Form SC 13D/A filed by ProSomnus Inc. (Amendment)

    SC 13D/A - ProSomnus, Inc. (0001934064) (Subject)

    12/8/23 4:15:31 PM ET
    $OSA
    Medical Specialities
    Health Care

    $OSA
    Financials

    Live finance-specific insights

    View All

    ProSomnus Reports Record Fourth Quarter and Fiscal Year 2023 Financial Results

    PLEASANTON, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ:OSA), the leading non-CPAP therapy™ for the treatment of Obstructive Sleep Apnea (OSA), today announced financial results for the fourth quarter and year ended December 31, 2023. Recent Business Highlights Generated record revenues of $7.8 million for the fourth quarter and $27.7 million for the fiscal year 2023, a 35% increase compared to $5.8 million for the fourth quarter 2022 and 43% increase compared to $19.4 million for fiscal year 2022. The quarter marked the eighth (8th) sequential quarter of record revenues.Continued focus on implementing reductions in operating expenses. Operating expenses, excludin

    3/26/24 4:05:00 PM ET
    $OSA
    Medical Specialities
    Health Care

    ProSomnus Reschedules Fourth Quarter and Fiscal Year 2023 Investor and Business Update Call

    PLEASANTON, Calif., March 15, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the "Company"), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced today it has postponed the release of its 2023 fourth quarter and full year financial results and the related investor conference call. The rescheduled call will be held after market close on Tuesday, March 26, 2024 at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Registration and dial-in information can be found on the investor relations website. Additionally, the Company will not be attending the Roth Conference. About ProSomnusProSomnus (NASDAQ: OSA) is the leading non-CPAP therapy for the treatment of Obstructiv

    3/15/24 8:01:20 PM ET
    $OSA
    Medical Specialities
    Health Care

    ProSomnus Announces Fourth Quarter and Fiscal Year 2023 Investor and Business Update Call and Participation at the 36th Annual ROTH Conference in March 2024

    PLEASANTON, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ:OSA), the leading non-CPAP therapy for the treatment of Obstructive Sleep Apnea (OSA), announced today that it will report its fourth quarter and fiscal year 2023 financial results and provide a business update before market open on Monday, March 18, 2024 at the 36th Annual ROTH Conference and via a live webcast. ProSomnus Chief Executive Officer, Len Liptak, and Chief Financial Officer, Brian Dow, will host a conference call at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time. Following the call, management will participate in the 36th Annual ROTH Conference, being held March 17-19, 2024. Fourth Quarter and Fisc

    2/20/24 4:05:00 PM ET
    $OSA
    Medical Specialities
    Health Care